Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.21 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

24 25 Next >

The Top 3 Biotech Stocks to Buy in April 2024 ↗

April 27, 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

Via InvestorPlace

3 Millionaire-Maker Biotech Stocks ↗

April 25, 2024

The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.

Via The Motley Fool

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

April 24, 2024

Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

These Biotech Stocks Could Soar 120% and 295%, According to Wall Street ↗

April 21, 2024

Catalysts lie ahead for both of these companies.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 19, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Is Iovance Biotherapeutics Stock a Buy Now? ↗

April 17, 2024

Let's find out if this biotech can keep up its recent momentum.

Via The Motley Fool

The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover

April 09, 2024

Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.

Via MarketBeat

Topics Cannabis

Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics ↗

April 05, 2024

These companies are in the early days of their growth stories.

Via The Motley Fool

2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street ↗

March 26, 2024

Find out why investment banks up and down Wall Street have big expectations for these stocks.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 22, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗

March 13, 2024

Via Benzinga

(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗

March 01, 2024

Via Benzinga

Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity ↗

February 29, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 19, 2024

Via Benzinga

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead ↗

March 18, 2024

This company's growth story is about to get moving with gusto.

Via The Motley Fool

Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗

March 14, 2024

Via Benzinga

Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗

March 07, 2024

Via Benzinga

Iovance Biotherapeutics: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

Iovance Biotherapeutics's Earnings: A Preview ↗

February 27, 2024

Via Benzinga

1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? ↗

March 07, 2024

Its revenue is set to grow, and one of its trials is no longer paused.

Via The Motley Fool

Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst ↗

March 06, 2024

With its first approval in hand, attention is now on the top line.

Via The Motley Fool

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

March 04, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Could Iovance Biotherapeutics Stock Help You Become a Millionaire? ↗

March 02, 2024

Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?

Via The Motley Fool

Iovance Biotherapeutics to Present at Upcoming Conferences

March 01, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Why Iovance Biotherapeutics Stock Got Trounced on Thursday ↗

February 29, 2024

A robust rally ended abruptly with the publication of the company's latest fundamentals.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? ↗

February 29, 2024

More gains might be on the way for this high-flying biotech stock.

Via The Motley Fool

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

February 28, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

3 Stocks Flashing Recent Insider Buying Signals ↗

February 27, 2024

One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company.

Via InvestorPlace

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.